Compare SAMG & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SAMG | ACOG |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Canada |
| Employees | 164 | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 130.9M |
| IPO Year | 2013 | N/A |
| Metric | SAMG | ACOG |
|---|---|---|
| Price | $14.47 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 31.8K | ★ 94.3K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 6.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $125,322,000.00 | $7,427,199.00 |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $7.48 | $101.16 |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $13.23 | $3.75 |
| 52 Week High | $19.20 | $11.54 |
| Indicator | SAMG | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 39.10 |
| Support Level | $13.32 | $5.66 |
| Resistance Level | $13.79 | $6.18 |
| Average True Range (ATR) | 0.38 | 0.44 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 100.00 | 20.62 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.